Ethena Labs, creator of the synthetic dollar USDe, has passed a rigorous SOC 2 Type II audit with zero exceptions, confirming strong operational security and controls over several months. This certification, rare in DeFi, enhances Ethena's credibility as it bridges decentralized finance with traditional institutions, supported by partnerships with Coinbase and Janus Henderson. The audit covers organizational controls beyond smart contracts, such as access management and incident response, signaling Ethena's readiness for institutional collaboration. The next step is whether Ethena will publicly share the full audit report or limit access to partners under NDA, which could set new transparency standards in DeFi.
Ethena Labs' SOC 2 Type II audit completion is notable. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Sep 14, 2026 23:23 WIB: out of 50 major cryptocurrencies, 26 rose and 23 fell. Notable movers include BAT at Rp1.386 with a -4.58% change, XTZ at Rp4.862 with a -4.55% change and 100% sell order activity, and KSM at Rp70.631 with a +4.50% change.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
